NICE proposes Mabthera use in additional chemo regimes
This article was originally published in Scrip
New draft guidance from the National Institute for Health and Clinical Excellence (NICE), the health technology agency for England and Wales, is proposing that Mabthera (rituximab) should be available in combination with a wider range of chemotherapy regimens to National Health Service patients with symptomatic stage III and IV follicular lymphoma. Stakeholders are invited to comment on the appraisal consultation document between 5 and 26 September, 2011 (www.nice.org.uk/guidance/index.jsp?action=article&o=56199).
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.